Dr. Stuart Titus, President and CEO of Medical Marijuana, Inc., will give a talk covering the potential market for CBD in the U.S. and worldwide.
The cannabis industry will descend on Medical Marijuana, Inc.’s hometown the weekend of August 6-7th when the Southern California Cannabis Conference and Expo comes to the San Diego Convention Center.
As part of Medical Marijuana, Inc.’s presence at the upcoming event, our president and CEO Dr. Stuart Titus will be giving a Medical Research and Cannabis presentation at noon, Sunday the 7th, on the conference’s main stage.
Titled “The Exploding Marketplace of Cannabidiol (CBD)”, Dr. Titus will begin his presentation by first exploring the historical use of cannabis and its eventual disappearance from medical use in America following prohibition in the 1930’s.
However, beginning in the 1940’s, the modern era of cannabis research begins in earnest with the isolation of the first few cannabinoids discovered, including CBN, CBD, and THC, leading to the discovery in the 1980’s of the endocannabinoid system, which is responsible for regulating a number of the body’s functions and establishing homeostasis.
This research would eventually culminate with the patent on the medical use of cannabinoids, patent #6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants”, which is owned by the U.S. government.
As Dr. Titus will reveal in his presentation, this early work forms the foundation for current medical research being done, including by Medical Marijuana, Inc. investment companies like Kannalife™ Sciences and AXIM® Biotechnologies.
Kannalife™ Sciences has acquired licenses on the ‘507 patent to develop cannabis-based pharmaceuticals for a pair of neurological diseases: hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE), the former being at the center of controversy between NFL players and the league over concussion and brain damage. To this end, Kannalife™ Sciences has created a synthetic form of cannabidiol, KLS-13019, which is 50 times more potent and 400 times safer than naturally occurring CBD.
AXIM® Biotechnologies is pursuing clinical trials for their MedChew® RX for the pain and spasticity associated with multiple sclerosis and an experimental topical treatment for skin conditions like eczema and psoriasis.
Dr. Titus shares his expertise and knowledge of the endocannabinoid system with our customers and shareholders in his weekly column, Dr. Titus’ Insights. Leave your questions with Dr. Titus for the opportunity to have them answered by our CEO.
Visit the Southern California Cannabis Conference and Expo website for more information on the event or to buy your tickets today.